Cingulate Inc. (CING) vs Gossamer Bio, Inc. (GOSS)

A side-by-side comparison of Cingulate Inc. and Gossamer Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CING

Cingulate Inc.

$66M

$4.92HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT

GOSS

Gossamer Bio, Inc.

$66M

$10.74HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT

Total return — CING vs GOSS

growth of $100 · dividends reinvested · last 5y

CING -99.6% (-66.1%/yr)GOSS -98.8% (-58.7%/yr)GOSS compounded faster over this window

CING GOSS

CING vs GOSS: by the numbers

•CING is the larger company ($66M vs $66M market cap).
•Both run net losses; CING's is the smaller (0.00% vs -235.00% net margin).

Metrics side by side

Valuation

Metric	CING	GOSS
P/S ratio	N/A	1.23
P/B ratio	2.82	N/A
EV / EBITDA	0.23	N/A

Profitability

Metric	CING	GOSS
Gross margin	0.00%	99.56%
Operating margin	0.00%	-336.81%
Net margin	0.00%	-235.00%
ROE	-122.71%	N/A
ROIC	-83.74%	N/A

Growth (annualized)

Metric	CING	GOSS
Total return CAGR (5Y)	N/A	-59.51%

Go deeper

Full CING analysis Full GOSS analysis Interactive comparison tool

Dig into the metrics

Cingulate ROE Gossamer Bio ROE Cingulate operating margin Gossamer Bio operating margin Cingulate revenue growth Gossamer Bio revenue growth Cingulate free cash flow Gossamer Bio free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.